期刊
ANGIOLOGY
卷 -, 期 -, 页码 -出版社
SAGE PUBLICATIONS INC
DOI: 10.1177/00033197231157473
关键词
atherosclerotic cardiovascular diseases; atherosclerosis; high-density lipoprotein subfractions; remodeling; reverse cholesterol transport
A low level of HDL-C is considered an independent biomarker of cardiovascular disease, and raising HDL-C has been recognized as a promising strategy to treat atherosclerotic cardiovascular diseases. However, increasing HDL-C levels does not necessarily reduce the risk of ASCVD, possibly due to the dysfunctional HDL particles in atherosclerotic patients that might even promote ASCVD. Therefore, it is necessary to comprehensively analyze the structure and function of HDL subfractions.
Numerous studies have shown that a low level of high-density lipoprotein cholesterol (HDL-C) is an independent biomarker of cardiovascular disease. High-density lipoprotein (HDL) is considered to be a protective factor for atherosclerosis (AS). Therefore, raising HDL-C has been widely recognized as a promising strategy to treat atherosclerotic cardiovascular diseases (ASCVD). However, several studies have found that increasing HDL-C levels does not necessarily reduce the risk of ASCVD. HDL particles are highly heterogeneous in structure, composition, and biological function. Moreover, HDL particles from atherosclerotic patients exhibit impaired anti-atherogenic functions and these dysfunctional HDL particles might even promote ASCVD. This makes it uncertain that HDL-raising therapy will prevent and treat ASCVD. It is necessary to comprehensively analyze the structure and function of HDL subfractions. We review current advances related to HDL subfractions remodeling and highlight how current lipid-modifying drugs such as niacin, statins, fibrates, and cholesteryl ester transfer protein inhibitors regulate cholesterol concentration of HDL and specific HDL subfractions.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据